# US 11,439,639 B2 · Pyrazine-containing compound > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,439,639 B2 - Document ID: US11439639B2 - Status: Granted - Kind: B2 - Application number: 17/472,422 - Filed: 2021-09-10 - Published: 2022-01-06 - Granted: 2022-09-13 - Earliest claimed: 2015-02-27 - Assignees: Calcimedica, Inc. - Applicants: CalciMedica, Inc. - Inventors: Gonul Velicelebi; Kenneth Stauderman; Michael Dunn; Jack Roos - Web page: https://patentgrep.com/patent/US11439639B2 ## CPC - A61K 31/497: containing further heterocyclic rings - A61K 31/415: 1,2-Diazoles - A61K 31/4155: non condensed and containing further heterocyclic rings - A61K 31/421: 1,3-Oxazoles, e.g. pemoline, trimethadione - A61K 31/427: not condensed and containing further heterocyclic rings - A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465) - A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone - A61K 31/485: Morphinan derivatives, e.g. morphine, codeine - A61K 31/506: not condensed and containing further heterocyclic rings - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes - C07D 401/04: directly linked by a ring-member-to-ring-member bond - C07D 405/04: directly linked by a ring-member-to-ring-member bond - C07D 413/14: containing three or more hetero rings - C07D 417/10: linked by a carbon chain containing aromatic rings - C07D 417/14: containing three or more hetero rings - C07D 491/04: Ortho-condensed systems - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08) - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract Compositions and methods related to the amelioration of pancreatitis through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may be used to ameliorate symptoms of acute or chronic pancreatitis or to reduce the chance or severity of pancreatitis in an individual at risk of the condition. In other embodiments, disclosed herein are compositions and methods related to the amelioration of viral diseases through the pharmaceutical manipulation of calcium signaling. In further embodiments, disclosed herein are compositions and methods related to the amelioration of Th17-induced diseases through the pharmaceutical manipulation of calcium signaling. ## Claims ### Claim 1 A method for treating renal failure in a subject, comprising administering to the subject a therapeutically effective amount of a compound having a chemical name of N-[5-(6-chloro-2,2-difluorobenzo[d]1,3-dioxolen-5-yl)pyrazin-2-yl](2-fluoro-6-methylphenyl)carboxamide or a pharmaceutically acceptable sale thereof, wherein the subject has renal failure as a secondary manifestation of pancreatitis resulting from an inflammatory response. ### Claim 2 (depends on 1) The method of claim 1, wherein the renal failure is severe chronic renal failure. ### Claim 3 (depends on 1) The method of claim 1, wherein the inflammatory response is a chronic inflammatory disease. ### Claim 4 (depends on 3) The method of claim 3, wherein the chronic inflammatory disease is T helper 17 cell (Th 17) induced. ### Claim 5 (depends on 4) The method of claim 4, wherein the Th17 induced chronic inflammatory disease is an autoimmune disorder. ### Claim 6 (depends on 1) The method of claim 1, wherein the inflammatory response is associated with a group of inflammatory mediators consisting of TNF-α and IL-1. ### Claim 7 (depends on 5) The method of claim 5, further comprising inhibiting Th17 differentiation. ### Claim 8 (depends on 1) The method of claim 1, wherein the compound is administered to achieve a plasma level concentration that is about 1 μM. ### Claim 9 (depends on 1) The method of claim 1, wherein the compound is administered to achieve a plasma level concentration that is from about 1 μM to about 2 μM. ### Claim 10 (depends on 1) The method of claim 1, wherein the compound is administered to achieve a plasma level concentration that is about 5 μM. ### Claim 11 A method for treating an autoimmune disease in a kidney in a subject, comprising administering to the subject a therapeutically effective amount of a compound having a chemical name of N-[5-(6-chloro-2,2-difluorobenzo[d]1,3-dioxolen-5-yl)pyrazin-2-y](2-fluoro-6-methylphenyl)carboxamide or a pharmaceutically acceptable sale thereof, wherein the autoimmune disease is Th17 induced. ### Claim 12 (depends on 11) The method of claim 11, wherein the autoimmune disease in the kidney is associated with an inflammatory response in the subject. ### Claim 13 (depends on 12) The method of claim 12, wherein the inflammatory response is a chronic inflammatory disease. ### Claim 14 (depends on 12) The method of claim 12, wherein the inflammatory response is associated with a group of inflammatory mediators further consisting of TNF-α and IL-1. ### Claim 15 (depends on 11) The method of claim 11, wherein the compound is administered to achieve a plasma level concentration that is about 1 μM. ### Claim 16 (depends on 11) The method of claim 11, wherein the compound is administered to achieve a plasma level concentration that is from about 1μM to about 2μM. ### Claim 17 (depends on 11) The method of claim 11, wherein the compound is administered to achieve a plasma level concentration that is about 5 μM.